1. Bridgeman, J. F., Rosen, A. M., Thorp, J. M.: Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia. LancetII, 502?506 (1972)
2. Denizot, M., Farre, J., Pometta, D., Wildi, E.: Clofibrate, nephrotic syndrome and histological changes in muscle. LancetI, 1326 (1973)
3. Green, K. G., Margetts, G.: Long-term follow-up of multicentre trial of ethyl-?-chlorophenoxyisobutyrate (clofibrate. ?Atromid?-S) and clofibrate plus androsterone (?Atromid?). In: Progress in biochemical pharmacology, Vol. 2 (eds. D. Kritchevsky, R. Paoletti, D. Steinberg), pp. 378?392. Basel Karger 1967
4. Guth, L., Samaha, F. J.: Procedure for the histochemical demonstration of actomyosin ATPase. Exp. Neurol.28, 365?367 (1977)
5. Hess, R., St�ubli, W., Reiss, W., Reiss, W.: Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature208, 856?858 (1965)